NasdaqGM - Delayed Quote USD

Connect Biopharma Holdings Limited (CNTB)

1.3400 -0.0100 (-0.74%)
At close: April 26 at 4:00 PM EDT
1.3300 -0.01 (-0.75%)
After hours: April 26 at 7:00 PM EDT

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Wubin Pan M.B.A., Ph.D. Co-Founder, President & Chairman of the Board of Directors -- -- 1965
Dr. Zheng Wei Ph.D. Co-Founder, CEO & Director -- -- 1964
Mr. Steven Chan Chief Financial Officer -- -- 1972
Mr. Jiang Bian J.D. General Counsel & Chief Compliance Officer -- -- --
Dr. Lei Sun Ph.D. VP of Biologics & Head of CMC -- -- 1964
Dr. Raul Collazo Ph.D. VP & Global Head of Medical Affairs -- -- --
Dr. Malinda V. Longphre Ph.D. VP & Head of US Clinical Operations -- -- --

Connect Biopharma Holdings Limited

12265 El Camino Real
Suite 350
San Diego, CA 92130
United States
858 727 1040 https://www.connectbiopharm.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
81

Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Corporate Governance

Connect Biopharma Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 16, 2024
Connect Biopharma Holdings Limited Earnings Call

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
EQ Equillium, Inc.
1.7100
-5.52%
 
MNOV MediciNova, Inc.
1.3100
-0.76%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
MAIA MAIA Biotechnology, Inc.
2.9400
+9.70%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9900
+0.34%